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ABSTRACT
For at least two decades, there has been an intense debate on whether and
how to include the value of lost productivity in economic evaluations. This
debate is often reﬂected in pharmacoeconomic guidelines, which have been
developed to indicate the methods and requirements for the design, execu-
tion, and reporting of economic evaluations in a particular country.
Objective: To examine what various national pharmacoeconomic guide-
lines recommend regarding the identiﬁcation, measurement, and valuation
of lost productivity.
Methods: First, the theoretical framework on how lost productivity can
be identiﬁed, measured, and valued is described. Second, a summary sheet
has been used to identify various pharmacoeconomic guidelines recom-
mendations regarding the value of lost productivity.
Results: Twenty-two of the 30 guidelines identiﬁed recommend perform-
ing economic evaluations using the societal perspective. Nevertheless, even
if the societal perspective is recommended, it is not always clear how the
value of lost productivity should be taken into account. Most guidelines
recommend including the costs of absenteeism from paid and/or unpaid
work. In addition, although no agreement exists on how lost productivity
should be valued, none of the guidelines recommended using the US panel
approach for the valuation of lost productivity.
Discussion: The different recommendations hinder international transfer-
ability of the value of lost productivity. This difﬁculty is mainly caused by
different recommendations regarding identiﬁcation and valuation. These
differences result from the debate and lack of consensus on including the
value of lost productivity losses in economic evaluations. It will become
easier to transfer data across jurisdictions if all data are reported
transparently.
Keywords: comparison, guidelines, lost productivity, transferability.
Introduction
During the last two decades, there has been disagreement about
whether or not the value of lost productivity should be included
in economic evaluations and, if so, how these losses should be
valued [1]. One of the areas of discussion is the methodology that
has been advocated for the valuation of these losses [1–3]. The
US panel states that lost productivity inﬂuences the health-related
quality of life of people and that consequently, the losses should
be assessed in the quality-adjusted life-year (QALY) [4], whereas
others state that the lost productivity should be incorporated in
the costs [1,2]. Furthermore, the adequate identiﬁcation of the
value of lost productivity, especially in the short term, is still an
under-researched area. Nevertheless, the importance of correct
identiﬁcation should not be underestimated. Due to the different
ideas about identiﬁcation, measurement, and valuation, pharma-
coeconomic guidelines differ in their recommendations on this
topic [1].
Several countries have developed pharmacoeconomic guide-
lines [5]. National guidelines are developed primarily to indicate
the requirements for the design, execution, and reporting of the
results of economic evaluations in a speciﬁc country [5,6]. These
guidelines are utilized to improve the quality of economic evalu-
ations by encouraging good research practice. This should lead
to greater standardization, which, in turn, should increase the
comparability of studies and may increase the generalizability of
results [6]. Results are considered generalizable if they can be
applied to other settings without any adjustments [7].
Nevertheless, country-speciﬁc guidelines may stipulate, in
addition to the use and presentation of local data, the use of
speciﬁc methods as well. As a result, the requirements stated in
various national guidelines are not always comparable [7,8].
Moreover, there are several factors that may cause variations in
the cost-effectiveness estimates of health technologies from place
to place, and these will hinder the transferability of economic
evaluations [7,9]. Data are considered transferable if they can be
adapted to apply to other settings or jurisdictions [7]. Therefore,
it can be considered reasonable for national guidelines to stipu-
late that economic evaluations be relevant to the local context as
well [7,9].
One of the possible differences between national guidelines
is the recommended perspective. When performing an economic
evaluation, an explicit statement should be given regarding the
perspective from which costs and effects are estimated. There is
a strong theoretical preference that economic evaluations
should be performed from a societal perspective, but many
studies are carried out from more narrow perspectives. This
theoretical preference for the societal perspective is related to
the foundations of economic evaluations in welfare economics,
which is concerned with the welfare of society [2,10]. There-
fore, an overall assessment of the efﬁciency of a technology
should consider the various consequences from a larger societal
perspective and not just for the individuals who are directly
involved [2]. As a consequence, when economic evaluations are
carried out from the societal perspective, the value of lost pro-
ductivity should be included in the analysis, which might not be
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the case when using a more narrow perspective [2,3]. See
Figure 1, section A “Perspective.”
The terms “production cost,” “productivity cost,” “produc-
tion loss,” and “productivity loss” all refer to the monetary
valuation of a reduction in productivity. In this respect, Brouwer
et al. deﬁne productivity costs as “costs associated with working
time lost and replacement costs due to illness, disability and death
of productive persons, both paid and unpaid” [11]. In contrast,
the term “value of lost production” refers to both the monetary
valuation and valuation in effects of a reduction in productivity.
Therefore, in this article, we will use the term “productivity costs”
and “(value of) lost productivity” accordingly.
Figure 1 Valuing health-related lost productivity.
520 Knies et al.
Considering the fact that productivity reduction related to
disease can be substantial—for example, the costs of lost pro-
ductivity can exceed health-care costs—clear guidance is needed
on how to value lost productivity in economic evaluations [12].
When various national guidelines have different recommenda-
tions regarding the identiﬁcation, measurement, and valuation of
lost productivity, it hinders or makes it harder to transfer data
across jurisdictions. In this study, 30 national pharmacoeco-
nomic guidelines were compared with each other regarding lost
productivity, and a summary sheet was used to identify the
recommendations in the various guidelines. Accordingly, the
objective of this study is to examine what the existing national
pharmacoeconomic guidelines recommend regarding the identi-
ﬁcation, measurement, and valuation of lost productivity.
First, the theoretical background of the value of lost produc-
tivity is described in three steps within the theoretical framework.
Second, the methodology section describes the requirements of
the national pharmacoeconomic guidelines and the development
of the summary sheet. In the results section, the different recom-
mendations of the guidelines regarding lost productivity are sum-
marized, and in the discussion, conclusions are drawn from the
results.
Theoretical Framework
Identiﬁcation
In section B “Identiﬁcation,” of Figure 1, the alternative opera-
tionalizations of lost productivity can be found. The value of lost
productivity is often divided into paid working time, nonpaid
working time, and leisure time [1,13,14]. Lost productivity in
paid working time can occur in the following situations: being
present at work but working at a reduced capacity due to health
problems (presenteeism) or being absent from work (absentee-
ism). In absenteeism, the distinction can be made between short-
term and long-term absenteeism, where short-term absenteeism
is being deﬁned as absenteeism shorter than 6 weeks. In addition,
mortality and permanent disability can be categorized as a kind
of long-term absenteeism. Moreover, transitions between these
types of reduced productivity are possible [1,14–16]. This divi-
sion is also useful for the identiﬁcation of lost productivity in
nonpaid labor.
One of the most common phenomena of lost productivity is
presenteeism in paid working time. There are two situations in
which presenteeism may occur: when health problems do not
result in absenteeism yet do result in lost productivity, and when
health problems cause not only absenteeism but also lost pro-
ductivity during a period of time before and after absence. Fur-
thermore, compensation mechanisms may limit productivity loss,
but it is unclear how effective these mechanisms are. When an
employee makes up for lost work by working overtime on his/her
return to the workplace, this may lead to additional costs for the
employer or to reduced leisure time. If the lost work is compen-
sated for during normal working hours, this may be carried out
during breaks or by working at a faster pace [17].
Identifying the value of lost productivity, in effect using a
single effect measure covering both the consequences of morbid-
ity and mortality, obviously leads to using the QALY concept. Of
course, the controversy—whether lost productivity should be
valued in monetary or effect terms—inﬂuences not only the iden-
tiﬁcation, but also the measurement and the valuation of lost
productivity [18–20].
Measurement in Costs and QALYs
Section C “Measurement,” of Figure 1, shows that, depending
on the identiﬁcation phase, lost productivity can be measured in
various ways. The most appropriate method for measuring the
value of lost productivity is still under discussion mainly because
the adequate measurement of short-term lost productivity is still
an under-researched area [1,2]. For paid labor, data from human
resource departments may be unreliable, and data on presentee-
ism and compensation mechanisms are mostly not taken into
account due to difﬁculties with measuring these types of lost
productivity. Therefore, many economic evaluations utilize
patient-reported measures of lost productivity [5]. Most of these
instruments assess the reduction in input due to absenteeism or
presenteeism. The problem is that hardly any of the existing
instruments have been completely validated. Furthermore, large
differences in productivity costs can be found depending on the
instrument used [21,22]. At the moment, questionnaires for
patient-reported data are an acceptable method for measuring
the value of lost productivity, taking into account that, in our
opinion, the ideal instrument would capture absenteeism, pre-
senteeism, and compensation mechanisms. The use of question-
naire for patient-reported lost productivity is the only method for
measuring lost productivity in nonpaid labor [5].
The measurement of the QALY may be realized through
randomized controlled trials, observational data, uncontrolled
experiments, and expert opinion, possibly in combination with
life expectancy data. The QALY weights must be preference
based, interval scaled, and measured or transformed into an
interval scale in which the score of 0.0 is the reference point for
“death” and the score of 1.0 indicates “perfect health” [4].
Valuation in Costs and QALYs
Section D “Valuation,” of Figure 1, indicates again that lost
productivity can be valued in costs and in QALYs. The most
frequently used methods for valuing productivity costs in paid
labor are the human capital approach (HCA) and the friction
cost method (FCM) [2]. The US panel approach is the only
method for the valuation of lost productivity in the QALY. An
overview of methods is given in Table 1.
Previous research has indicated that the application of either
the HCA or the FCM leads to different estimates of productivity
losses. For example, in a Canadian study by Goeree et al., it was
calculated that the HCA resulted in a 69 times higher estimation
than the FCM [26]. In an article by Koopmanschap et al., several
ratios ranging from 1.03 to 3273 were presented, in which the
FCM showed lower estimations of the productivity losses than
did the HCA [1]. Furthermore, Hutubessy et al. calculated the
annual productivity losses of back pain in The Netherlands using
both the HCA and FCM. The total costs for the HCA, including
both absenteeism and disability, were US$1545 million, whereas
the FCM showed costs of US$842 million [27].
Although it can be considered as a kind of absenteeism, the
valuation of lost productivity due to mortality is not often taken
into account when calculating lost productivity [2,28]. Further-
more, in most economic evaluations, little attention is paid to
presenteeism. Nevertheless, for some chronic diseases, the value
of lost productivity due to presenteeism may be comparable or
even higher than the costs of absenteeism and direct health-care
costs combined [17,22,28]. Presenteeism is most frequently men-
tioned and incorporated by advocates of the FCM [1,2]. Com-
pensation mechanisms may lead to lower estimates of lost
productivity. Therefore, to calculate possible cost reductions, one
should calculate the costs of compensation and the gains of the
reduced value of the lost productivity. The net result of these two
parts will be the reduction in costs as a result of compensation
[17].
When using the societal perspective, lost productivity in
nonpaid labor becomes relevant [2]. Two monetary methods for
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valuing lost productivity in nonpaid labor are the opportunity
costs method and the shadow price method. In using the oppor-
tunity costs method, the input, or the sacriﬁced time, is valued
and with the shadow price method, the output, i.e., the com-
modities not produced, are valued. Shadow prices are often
calculated using the wages of household help or by the gross
wage rate of individuals with paid work that closely matches the
unpaid work [2,28]. Opportunity costs are calculated using the
value of forgone leisure time or the net wage that would be
obtained by an individual if he/she was in paid employment [2].
According to the US panel, the effects of a health intervention
on lost productivity are incorporated in the denominator of the
cost-effectiveness ratio [4]. Therefore, the full impact of morbid-
ity changes should be valued using preference-weighted measures
of health-related quality of life [4,20]. Furthermore, changes in
life expectancy are also included in the denominator and should
therefore not be included in the numerator [4]. Nevertheless,
using the US panel approach, time spent by the patient in receiv-
ing treatment should be captured in the numerator by calculating
the opportunity costs [4,20].
Methods
The International Society for Pharmacoeconomics and Outcomes
Research (ISPOR) presents an overview of pharmacoeconomic
guidelines around the world on their Web site at: http://
www.ispor.org/PEguidelines/index.asp. These pharmacoeco-
nomic guidelines may be government regulatory documents,
publications, or suggested guidance or best practices for conduct-
ing and using economic evaluations in health care and reimburse-
ment decisions. On this Web page, a comparative table of 32
main features of the guidelines is presented. Furthermore, the
hyperlinks or the publication references are given for all guide-
lines [29]. Only the pharmacoeconomic guidelines that are
included on this section of the ISPOR Web site were used for
comparison. Consequently, most guidelines could be found using
the hyperlinks or references given in the list of country-speciﬁc
pharmacoeconomic guidelines on the ISPOR Web site. Pharma-
coeconomic guidelines that could not be obtained from the
ISPOR Web site (Denmark, Finland, and Switzerland) were
retrieved by contacting researchers located in the respective
countries. The guidelines of Brazil, China, Cuba, the Slovak
Republic, and South Korea were available only in their national
language. To retrieve all relevant information from these guide-
lines, native or ﬂuent speakers were contacted to obtain transla-
tions (see acknowledgments).
We developed a sheet to systematically summarize the recom-
mendations related to the perspective and identifying, measuring,
and valuing lost productivity as described in the guidelines. The
summary sheet contained questions about lost productivity
resulting from absenteeism, as well as lost productivity related to
unpaid labor, compensation mechanisms, and presenteeism. The
summary sheet made it possible to include other remarks related
to the value of lost productivity. Each pharmacoeconomic guide-
line was evaluated using this summary sheet, which will be made
available online in the supporting information at: http://www.
ispor.org/Publications/value/ViHsupplementary/ViH13i5_Knies.
asp.
Results
In total, 30 national pharmacoeconomic guidelines on how to
perform economic evaluations were identiﬁed for the compari-
son. The vast majority of the guidelines, 23, were guidelines from
European and Northern American countries. The other seven
guidelines were developed in Asia, Oceania, or Latin America.
The guideline of China is not included in the comparison,
because the researchers contacted did not respond to our request
for retrieving the required information from the guideline.
Perspective of Economic Evaluations
In total, 22 of the 30 received guidelines recommended perform-
ing economic evaluations using the societal perspective [30–51].
Table 1 Methods for valuing lost productivity in economic evaluations
Human capital approach Friction cost method US panel approach
Valuation Valuation in monetary way Valuation in QALY
Calculation Multiply gross wage by number of sick days
[2]; estimation of value of all lost
production [3]
Value productivity losses of individuals with ill
health during friction period [2]
Productivity losses should be valued through
a generic preference-based measure [2]
Description Value changes in the amount of time
individuals are able to allocate to paid
work as a result of illness [2]
Measure of potential value of productivity
loss due to illness [2]
Friction period: time it takes to replace and
to train a replacement worker [2]
Assumes that everyone can be replaced [5]
Compensation mechanisms included in the
valuation of changes in paid working time
[2]
Time costs associated with morbidity
assessed within QALY and placed in
denominator [23]
Separation of impact of illness on quality of
life from effects on role function is difﬁcult
[23]
Background Based on neoclassical theory [2]
Assumed that there is no unemployment [3]
Developed as alternative for perceived
roughness of human capital approach [2]
Assumes that absenteeism reduces the
effective labor time less than
proportionally [24]
Monetary valuation of productivity losses
results in double counting if QALY is used
as measure of beneﬁt [2]
Advantage Relatively easy method to apply [2,5]
Useful for estimating productivity losses for
unpaid labor [3]
More realistic method for quantifying
production losses [3]
No double counting of productivity losses
possible, because these losses are included
in QALY [2]
Disadvantage Overestimation of costs because
compensation mechanisms are not taken
into account [25]
Overestimation of costs by death or
disablement [5]
Indirect costs for people outside labor force
not included [24]
Rejects the key tenets of conventional
microeconomic theory [2]; no foundation
in economic theory [24]
No overall agreement with assumptions used
[23,24]
Underestimation of costs, because net wages
and not the gross wages will be
incorporated [2]; not always the link
between inability to work and loss of
income [2]
Not in agreement with the common view on
the inclusion of costs [5]
QALY, quality-adjusted life-year.
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Nevertheless, the societal perspective is not the preferred perspec-
tive in all these guidelines. The guidelines that do not require or
suggest the societal perspective often recommend performing
economic evaluations from the perspective of the payer or of the
health-care sector [52–58]. As a result, these guidelines do not
mention how the value of lost productivity should be included
and were therefore not included in the rest of the comparison.
Nevertheless, even if the societal perspective is recommended, it
is not always clear if and how lost productivity should be taken
into account. For example, the Cuban guideline indicates that the
societal perspective should be used, but the guideline does not
indicate which costs should be identiﬁed, measured, or valued.
Nevertheless, aspects of different costing methods, as, for
example, the HCA, are detailed in the Appendix at: http://www.
ispor.org/Publications/value/ViHsupplementary/ViH13i5_Knies.
asp [40]. In addition, several guidelines that recommend using
the societal perspective state that productivity losses should not
be included in the base-case analysis [30,31,33,43,44,48,50].
Other guidelines state that the value of lost productivity should
be taken into account only if it is relevant to the study question
or if it is clear that productivity has changed because of the
disease or treatment [32,37,42,44,45]. Figure 2 shows the
process of handling and comparing the pharmacoeconomic
guidelines as carried out in study.
Identiﬁcation, Measurement, and Valuation of
Lost Productivity
As indicated in the theoretical framework, lost productivity can
be related to paid and nonpaid working time, and to leisure time.
The distinctions of different types of lost productivity are not
clear in all guidelines. For example, in the Austrian guideline, no
clear difference is made between short-term and long-term absen-
teeism. Most guidelines, as can be seen in Table 2, recommend
including the costs of absenteeism. Nevertheless, some guidelines
simply state that the value of lost productivity should be included
Figure 2 Processing of pharmacoeconomic
guidelines.
Table 2 Identiﬁcation of lost productivity in paid work as indicated in guidelines
Absenteeism
Presenteeism Mortality Compensation
Permanent
functional
impairment Unclear†Short Long Unclear*
Austria [51] x x x
Brazil [38] x x
Cuba [40] x
Denmark [32] x
Finland [43] x
France [34] x
Germany [41] x x
Hungary [50] x x
Ireland [45] x
Italy [35] x
The Netherlands [36] x x x
Norway [31] x x x x
Poland [44] x
Portugal [37] x
Russia [49] x x x
Slovak Republic [42] x
South Korea [30] x x x
Spain [47] x
Sweden [39] x
Switzerland [48] x x x
Thailand [46] x x
United States [33] x x
*Unclear what kind of absenteeism should be included.
†Unclear whether lost productivity should be included.
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in the analysis, but do not indicate which costs should be
identiﬁed.
The results shown in Table 2 make clear that, for example,
the inclusion of presenteeism and compensation mechanisms is
not consistently recommended. Nevertheless, when looking at
the recommendations in detail, several similarities can be identi-
ﬁed. The Hungarian, Dutch, Norwegian, South Korean, and
American guidelines all recommend including short-term and
long-term absenteeism. The guidelines of Austria, Brazil,
Finland, France, Germany, Italy, Russia, the Slovak Republic,
Switzerland, and Thailand state that absenteeism should be
included, but do not distinguish between short-term and long-
term absenteeism. Presenteeism should be included according to
the guidelines of Germany, Russia, and Switzerland. In addition,
the guidelines of Austria, Brazil, The Netherlands, Norway,
Russia, South Korea, Switzerland, and Thailand recommend
including mortality. Only the Austrian guidelines state that com-
pensation mechanisms should be taken into account. The Nor-
wegian guidelines are the only one that state that permanent
functional impairment should be included as part of lost produc-
tivity. In the guidelines of Cuba, Denmark, Ireland, Poland, Por-
tugal, Spain, and Sweden, it is not clear how lost productivity
should be taken into account. Finnish guidelines indicate that not
only should the value of lost productivity of paid work be iden-
tiﬁed and valued, but also the value of leisure time lost because of
disease. Nevertheless, it is not clearly stated how this should be
done. The Russian guidelines recommend including the costs of
absence from work for family members and other caregivers.
Measuring and valuing lost productivity. As previously indi-
cated, not all guidelines recommending the societal perspective
indicate which productivity losses should be included, and this is
also the case for the valuation of lost productivity. In the majority
of the guidelines, there is no description of how lost productivity
should be measured and valued; this is clariﬁed only in the
national guidelines from France and South Korea. The French
guidelines recommend using surveys to measure lost productivity
in economic evaluations. Furthermore, the guidelines of South
Korea state that the methodology for measuring the value of lost
productivity depends on the cost items and the availability of
data. Nevertheless, questionnaires, databases, surveys, and
expenditure diaries are all mentioned as suitable methods.
The results in Table 3 show that 11 guidelines recommend
following the HCA, 6 guidelines recommend the FCM, and none
of the guidelines recommend the US panel approach. Neverthe-
less, in six guidelines, it is not clear which method should be used
to value lost productivity.
Although, for example, the Swiss guidelines do not indicate
how lost productivity should be measured and valued, lost pro-
ductivity is referred to as indirect costs. The Russian and the
South Korean guidelines make no mention of the three methods
for measuring and valuing productivity losses but recommend
using opportunity costs. The remaining guidelines recommend-
ing a societal perspective do not indicate how lost productivity
should be valued.
Discussion
Our study, examining what various national pharmacoeconomic
guidelines recommend regarding the identiﬁcation, measurement,
and valuation of lost productivity, clearly indicated differences
between the guidelines. It can be concluded that the different
recommendations hinder the transferability of data regarding the
value of lost productivity. This is mainly caused by differences in
the recommendations in the several guidelines. These differences
reﬂect the debate on including the value of lost productivity in
economic evaluations. As a result, no consensus exists among
researchers, which has led to different recommendations.
To begin with, not all guidelines recommend using the soci-
etal perspective. The use of the societal perspective is the most
comprehensive option when performing economic evaluations,
thus taking the value of lost productivity into account. Never-
theless, the decision for the perspective is not the only choice that
is relevant for the value of lost productivity. Although the Cana-
dian guidelines recommend using the perspective of the health-
care sector, the guidelines include recommendations on the
identiﬁcation and valuation of lost productivity [54]. Further-
more, some guidelines recommending the societal perspective do
not specify how the value of lost productivity should be included
in economic evaluations, whereas other guidelines have included
only a few lines or a small paragraph on the subject. As a result,
the information is often not clear or incomplete, leaving substan-
tial degrees of freedom on exactly how to calculate the value of
lost productivity.
Signiﬁcant differences exist between the guidelines on all
aspects of identiﬁcation, measurement, and valuation of lost
productivity. As recommendations on the identiﬁcation of lost
productivity differ greatly, this inﬂuences the ﬁnal estimation. In
addition, the different recommendations regarding the valuation
of productivity losses will also result in different estimates. Pre-
vious research, as indicated in the theoretical framework, has
shown that the application of the HCA or of the FCM leads to
different estimates of productivity losses [1,26,27]. Furthermore,
our results indicate that problems could arise concerning the
transferability of data when the guidelines are complied with in
all economic evaluations. As a consequence, if there is disagree-
ment between the guidelines on the identiﬁcation and valuation
of lost productivity, it will be difﬁcult to use these results in other
countries. In addition, none of the 22 guidelines recommending a
societal perspective indicate that the US panel approach should
be used for valuing lost productivity. Therefore, it can be con-
cluded that in all guidelines, lost productivity should be valued in
costs and not in effects—despite concerns that the monetary
valuation of lost productivity might result in double counting.
Table 3 Measurement and valuation of lost productivity
HCA FCM
US
panel
Other
method
Not
clear
Austria [51] x x
Brazil [38] x
Cuba [40] x
Denmark [32] x x
Finland [43] x
France [34] x
Germany [41] x
Hungary [50] x
Ireland [45] x
Italy [35] x
The Netherlands [36] x
Norway [31] x x
Poland [44] x
Portugal [37] x
Russia [49] x
Slovak Republic [42] x
South Korea [30] x
Spain [47] x
Sweden [39] x
Switzerland [48] x
Thailand [46] x
United States [33] x
FCM, friction cost method; HCA, human capital approach.
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For several reasons, only national pharmacoeconomic guide-
lines that are listed on the ISPOR Web site are included in this
comparison, meaning that material from textbooks and national
submission guidelines were not included. The national pharma-
coeconomic guidelines have been developed by national govern-
ments, representative organizations of governments, or
professional organizations, but they could also be publications or
documents with suggested guidance or best practices. We decided
to use the list of guidelines of the ISPOR Web site, because we
expect that national pharmacoeconomic guidelines are more
often utilized as guidance for economic evaluations than are
textbooks, particularly for the purpose of policy decision-
making. Furthermore, national guidelines indicate more clearly
the viewpoints of researchers or decision-making bodies on how
economic evaluations should be performed within a speciﬁc juris-
diction than do textbooks, usually written by researchers without
any jurisdiction in mind.
Due to the diversity of the recommendations in the guidelines,
a lot of variation exists in the design of economic evaluations.
The differences are mainly caused by some guidelines’ instruction
to use speciﬁc methods or to perform economic evaluations from
a limited and only locally relevant perspective. Therefore, it is
advisable that some recommendations in the pharmacoeconomic
guidelines become more standardized and comparable. This can
be achieved by developing international pharmacoeconomic
guidelines. Such international guidelines could address the
minimum requirements or minimum package that an economic
evaluation should fulﬁll, and of course, national, additional
requirements could guide adjustments to speciﬁc jurisdictions.
One topic that certainly needs to be addressed is the inclusion of
the value of lost productivity in economic evaluations. An
unequivocal description of how to include the value of lost
productivity will beneﬁt the transferability of these data. Never-
theless, it will be difﬁcult to develop such a guideline, because of
the different viewpoints on the requirements of a good economic
evaluation. This hampers the possibility, for the time being, of
reaching consensus on a European or international level. Never-
theless, several international organizations, like ISPOR and the
European network for Health Technology Assessment, are
paying attention to developing unequivocal methods and guide-
lines for economic evaluations.
Furthermore, more attention should be paid to other suitable
solutions for reducing the differences between pharmacoeco-
nomic guidelines. One option is to identify the fundamental
differences regarding the identiﬁcation, measurement, and valu-
ation of lost productivity. Nevertheless, it will be necessary for all
guidelines that recommend the societal perspective to indicate
clearly if and how lost productivity should be identiﬁed, mea-
sured, and valued. This can be seen as the ﬁrst step toward
ﬁnding possible solutions for dealing with these differences. By
identifying the fundamental differences, it might be easier to
come to consensus regarding some key points. Of course, more
insight regarding the alternative methods available is warranted
through research on the validity and reliability of measuring and
valuing lost productivity.
In addition, it would be easier to decide if data from other
jurisdictions can be transferred if all the data are reported trans-
parently. This would help to assess if data can be used elsewhere.
Therefore, it would be advisable to have minimum requirements
for the reporting of economic evaluations in journals. These
requirements should indicate which parts of economic evaluations
should be described in detail. At the same time, there should be
some focus on developing general guidelines, and more research
should be carried out regarding the fundamental differences in
recommendations on including the value of lost productivity.
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